Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 2
2021 2
2022 7
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Antifungal Drugs TDM: Trends and Update.
Kably B, Launay M, Derobertmasure A, Lefeuvre S, Dannaoui E, Billaud EM. Kably B, et al. Ther Drug Monit. 2022 Feb 1;44(1):166-197. doi: 10.1097/FTD.0000000000000952. Ther Drug Monit. 2022. PMID: 34923544 Review.
Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial.
Azizi M, Mahfoud F, Weber MA, Sharp ASP, Schmieder RE, Lurz P, Lobo MD, Fisher NDL, Daemen J, Bloch MJ, Basile J, Sanghvi K, Saxena M, Gosse P, Jenkins JS, Levy T, Persu A, Kably B, Claude L, Reeve-Stoffer H, McClure C, Kirtane AJ; RADIANCE-HTN Investigators. Azizi M, et al. Among authors: kably b. JAMA Cardiol. 2022 Dec 1;7(12):1244-1252. doi: 10.1001/jamacardio.2022.3904. JAMA Cardiol. 2022. PMID: 36350593 Free PMC article. Clinical Trial.
Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.
Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, Rump LC, Persu A, Basile J, Bloch MJ, Daemen J, Lobo MD, Mahfoud F, Schmieder RE, Sharp ASP, Weber MA, Sapoval M, Fong P, Pathak A, Lantelme P, Hsi D, Bangalore S, Witkowski A, Weil J, Kably B, Barman NC, Reeve-Stoffer H, Coleman L, McClure CK, Kirtane AJ; RADIANCE-HTN investigators. Azizi M, et al. Among authors: kably b. Lancet. 2021 Jun 26;397(10293):2476-2486. doi: 10.1016/S0140-6736(21)00788-1. Epub 2021 May 16. Lancet. 2021. PMID: 34010611 Clinical Trial.
Ceftazidime dosing in obese patients: is it time for more?
Fanton D'Andon C, Correia P, Rigaill J, Kably B, Perinel-Ragey S, Launay M. Fanton D'Andon C, et al. Among authors: kably b. Expert Opin Drug Metab Toxicol. 2022 Apr;18(4):277-284. doi: 10.1080/17425255.2022.2080052. Epub 2022 May 30. Expert Opin Drug Metab Toxicol. 2022. PMID: 35583387 Review.
Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing.
Lane D, Lawson A, Burns A, Azizi M, Burnier M, Jones DJL, Kably B, Khunti K, Kreutz R, Patel P, Persu A, Spiering W, Toennes SW, Tomaszewski M, Williams B, Gupta P, Dasgupta I; Endorsed by the European Society of Hypertension (ESH) Working Group on Cardiovascular Pharmacotherapy and Adherence. Lane D, et al. Among authors: kably b. Hypertension. 2022 Jan;79(1):12-23. doi: 10.1161/HYPERTENSIONAHA.121.17596. Epub 2021 Nov 5. Hypertension. 2022. PMID: 34739765 Free article. Review.
15 results